Indaptus Therapeutics, Inc. (INDP)
Largest Insider Buys in Sector
INDP Stock Price History Chart
INDP Stock Performance
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Insider Activity of Indaptus Therapeutics, Inc.
Over the last 12 months, insiders at Indaptus Therapeutics, Inc. have bought $216,388 and sold $0 worth of Indaptus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Indaptus Therapeutics, Inc. have bought $163,428 and sold $100,043 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Anderson Glen R. (10 percent owner) — $216,388.
The last purchase of 23,934 shares for transaction amount of $56,006 was made by Anderson Glen R. (10 percent owner) on 2023‑08‑14.
List of Insider Buy and Sell Transactions, Indaptus Therapeutics, Inc.
| 2023-08-14 | Anderson Glen R. | 10 percent owner | 23,934 0.2688% | $2.34 | $56,006 | -8.47% | ||
| 2023-08-11 | Anderson Glen R. | 10 percent owner | 35,064 0.3798% | $2.12 | $74,336 | -1.30% | ||
| 2023-08-10 | Anderson Glen R. | 10 percent owner | 44,354 0.482% | $1.94 | $86,047 | +2.71% | ||
| 2022-12-01 | Litchev Boyan Vesselinov | Chief Medical Officer | 500 0.0063% | $1.87 | $935 | +8.94% | ||
| 2022-11-22 | Litchev Boyan Vesselinov | Chief Medical Officer | 500 0.0061% | $1.83 | $915 | +4.95% | ||
| 2022-11-21 | Meckler Jeffrey A | CEO and Director | 9,600 0.122% | $1.90 | $18,240 | +5.25% | ||
| 2022-11-18 | Meckler Jeffrey A | CEO and Director | 400 0.0047% | $1.76 | $705 | +4.97% | ||
| 2022-09-08 | Meckler Jeffrey A | CEO and Director | 10,308 0.1329% | $2.80 | $28,862 | -29.85% | ||
| 2022-09-07 | Linscott Walt Addison | Chief Business Officer | 150 0.0018% | $2.62 | $393 | -29.58% | ||
| 2022-09-06 | Meckler Jeffrey A | CEO and Director | 8,632 0.1092% | $2.57 | $22,184 | -25.00% | ||
| 2022-06-06 | Meckler Jeffrey A | CEO and Director | 19,727 0.2371% | $2.63 | $51,882 | -28.68% | ||
| 2022-03-02 | Litchev Boyan Vesselinov | Chief Medical Officer | 50 0.0006% | $4.09 | $205 | -42.65% | ||
| 2022-02-01 | Sale | Newman Michael James | CSO and Director | 14,130 0.1722% | $5.00 | $70,692 | -49.70% | |
| 2022-01-31 | Sale | Newman Michael James | CSO and Director | 5,870 0.0712% | $5.00 | $29,351 | -49.90% | |
| 2022-01-31 | Litchev Boyan Vesselinov | Chief Medical Officer | 100 0.0011% | $4.65 | $465 | -49.90% | ||
| 2021-11-18 | Meckler Jeffrey A | CEO and Director | 11,187 0.2847% | $5.82 | $65,108 | -44.81% | ||
| 2021-09-14 | Meckler Jeffrey A | CEO and Director | 12,000 0.2842% | $7.00 | $84,000 | -43.28% |
Insider Historical Profitability
| Anderson Glen R. | 10 percent owner | 1190400 14.1697% | $2.37 | 3 | 0 | |
| Newman Michael James | CSO and Director | 1368356 16.2879% | $2.37 | 0 | 2 | |
| Meckler Jeffrey A | CEO and Director | 75374 0.8972% | $2.37 | 7 | 0 | <0.0001% |
| Litchev Boyan Vesselinov | Chief Medical Officer | 1150 0.0137% | $2.37 | 4 | 0 | <0.0001% |
| Linscott Walt Addison | Chief Business Officer | 150 0.0018% | $2.37 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $574,034.00 | 3 | 256,265 | 0% | +$0 | <0.0001 | |
| Investment House Llc | $229,459.00 | 1.2 | 102,437 | 0% | +$0 | 0.01 | |
| Geode Capital Management | $122,699.00 | 0.64 | 54,767 | 0% | +$0 | <0.0001 | |
| Strategy Asset Managers, LLC. | $101,553.00 | 0.53 | 45,336 | 0% | +$0 | 0.02 | |
| Renaissance Technologies | $58,000.00 | 0.31 | 26,100 | -11.22% | -$7,333.33 | <0.0001 | |
| Vivaldi Capital Management | $51,600.00 | 0.28 | 24,000 | 0% | +$0 | 0.02 | |
| Virtu Financial Llc | $32,000.00 | 0.17 | 14,232 | New | +$32,000.00 | <0.01 | |
| State Street | $29,284.00 | 0.15 | 13,073 | -32.87% | -$14,336.24 | <0.0001 | |
| Tower Research Capital | $9,108.00 | 0.05 | 4,066 | -13.42% | -$1,411.22 | <0.0001 | |
| UBS | $4,337.00 | 0.02 | 1,936 | -47.66% | -$3,949.45 | <0.0001 | |
| Morgan Stanley | $1,981.00 | 0.01 | 884 | 0% | +$0 | <0.0001 | |
| Bangor Savings Bank | $896.00 | 0.01 | 400 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $235.00 | <0.01 | 105 | +0.96% | +$2.24 | <0.0001 | |
| JPMorgan Chase | $31.00 | <0.01 | 14 | +55.56% | +$11.07 | <0.0001 | |
| Group One Trading | $16.00 | <0.01 | 7 | 0% | +$0 | <0.0001 | |
| Qube Research & Technologies | $2.00 | <0.01 | 1 | 0% | +$0 | <0.0001 |